Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that all three patients from the non-randomized cohort of the MOJAVE study were successfully treated with DSR 2.0.
Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that all three patients from the non-randomized cohort of the MOJAVE study were successfully treated with DSR 2.0.